Green Plains (GPRE) Announces Restructing

Green Plains Inc. has completed its acquisition of Green Plains Partners LP, the company announced today. The completion of the transaction resulted in the partnership becoming an indirect wholly owned subsidiary of Green Plains, with the partnership's common units no longer being listed on the NASDAQ.

As a result of the acquisition, Green Plains acquired all of the publicly held common units of the partnership not already owned by Green Plains and its affiliates. The exchange involved a combination of 0.405 shares of Green Plains common stock and $2.00 in cash, along with an amount of cash equal to unpaid distributions from the end of the last quarter for each outstanding common unit.

Following the completion of the merger, Green Plains provided insight into its focus as a leading biorefining company. "Green Plains is a leading biorefining company focused on the development and utilization of fermentation, agricultural and biological technologies in the processing of annually renewable crops into sustainable value-added ingredients," the company stated.

The company's stock experienced a -0.6% movement following the announcement and is currently trading at a price of $23.49 per share.

The company's full 8-K submission is available here.

2018 2019 2020 2021 2022 2023
Revenue (MM) $2,984 $2,417 $1,924 $2,827 $3,663 $3,497
Revenue Growth n/a -18.99% -20.42% 46.96% 29.56% -4.52%
Operating Margins 3% -6% -6% 1% -3% -3%
Net Margins 1% -7% -6% -2% -3% -4%
Net Income (MM) $16 -$167 -$109 -$66 -$127 -$139
Net Interest Expense (MM) $87 $40 $40 $67 $33 $35
Depreciation & Amort. (MM) $98 $72 $78 $92 $93 $101
Diluted Shares (MM) 41 38 35 47 56 67
Free Cash Flow (MM) -$2 -$85 -$12 -$183 -$143 -$58
Capital Expenditures (MM) $41 $75 $111 $187 $212 $107
Current Ratio 1.45 1.23 1.42 2.37 1.91 1.88
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS